HSPA5 and neoplasm: Selective inhibitors and antibodies targeting GRP78 have demonstrated significant potential, offering valuable insights for future therapeutic strategies by disrupting key cancer cell pathways, inhibiting tumor growth, and enhancing the efficacy of existing therapies [171].